Nervous System News and Research

Latest Nervous System News and Research

InvestorSoup.com announces investment report featuring Somaxon Pharmaceuticals

InvestorSoup.com announces an investment report featuring Somaxon Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

19 Mar 2010

FDA approves Somaxon Pharmaceuticals' Silenor for treatment of insomnia

Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.

19 Mar 2010

Acne drug prevents HIV breakout

Johns Hopkins scientists have found that a safe and inexpensive antibiotic in use since the 1970s for treating acne effectively targets infected immune cells in which HIV, the virus that causes AIDS, lies dormant and prevents them from reactivating and replicating.

18 Mar 2010

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

StemCells, Inc. announced today that the United Kingdom (UK) Intellectual Property Office has granted patent number GB2451523 with broad claims covering true (germline competent) rat stem cells and genetically engineered rats derived from these cells. The patented technology is expected to have significant utility to academic and pharmaceutical industry researchers by enabling them to create novel rat models for the study of human diseases. Both mice and rats are used by scientists to model various human diseases.

18 Mar 2010

Positive preliminary results from MediciNova's Phase Ib clinical trial of MN-221 for COPD

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today reported positive preliminary results from a Phase Ib clinical trial to evaluate the safety and efficacy of MN-221 in patients with stable, moderate to severe chronic obstructive pulmonary disease (COPD). There were no clinically significant safety concerns noted. Preliminary results demonstrated clinically significant improvements in percent change in forced expiratory volume in one second (FEV(1)).

18 Mar 2010

Findings from Study 305 evaluating the effect of Northera reported

Chelsea Therapeutics International, Ltd. reported findings from Study 305, a study evaluating the effect of Northera™ (Droxidopa), an investigational agent being studied for the treatment of neurogenic orthostatic hypotension (NOH), on patients' 24-hour blood pressure (BP) profile.

18 Mar 2010

Toxins released by certain microalgae can contaminate seafood and become toxic to humans

Toxins released by certain microalgae can contaminate fish and shellfish which then become toxic to humans. Researchers from CNRS and CEA have, for the first time, identified the mechanisms of action of two of these toxins.

18 Mar 2010

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.

17 Mar 2010

CNS Network purchases Logos Technologies' pro-active EDC system for streamlining clinical trials

It is announced today that CNS Network has purchased ALPHADAS®, Logos Technologies Inc’s early phase, e-source data capture system and site automation tools to accelerate and streamline its clinical trials. ALPHADAS is to be implemented in their Orange County Research Center, California, USA.

17 Mar 2010

StockPreacher.com: ACAD reports net loss of $8.7M for fourth-quarter of 2009

StockPreacher.com announces an investment report featuring ACADIA Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

17 Mar 2010

Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications

Protalix BioTherapeutics, Inc. announced today that it has initiated a phase I clinical trial of PRX-105, the Company's plant cell expressed pegylated recombinant human acetylcholinesterase product candidate in development for biodefense indications. The trial is designed to study the safety of PRX-105 by administering a bolus intravenous injection of PRX-105 in healthy volunteers.

17 Mar 2010

Researchers identify a novel way to study species-specific reproductive behavior

Researchers at the California Institute of Technology (Caltech) and the University of California, San Diego (UCSD) have discovered that injecting a simple hormone into leeches creates a novel way to study how hormones and the nervous system work together to produce species-specific reproductive behavior.

17 Mar 2010

Blocking RhoA enzyme increases survival in SMA mouse model

Scientists from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa have identified a promising new approach for developing drugs to treat Spinal muscular atrophy (SMA), the leading inherited cause of death in infants and toddlers. Dr. Rashmi Kothary and his doctoral student Melissa Bowerman have found that an enzyme called RhoA is overly active in a mouse model of the disease and blocking this enzyme can greatly increase survival. The study is published in Human Molecular Genetics.

16 Mar 2010

CogniFit Personal Coach brain training software improves cognitive function of MS patients

CogniFit™, Inc., a leading maker of Brain Fitness Software (www.cognifit.com), announced a new, independent study that shows CogniFit Personal Coach brain training software improves the cognitive function and skills of Multiple Sclerosis (MS) patients.

16 Mar 2010

Minimal improvements made in survival rates of AYA population with cancer

Despite cancer survival rates increasing dramatically for children and older adults in the last 20 years, there has been minimal improvement in the survival rates in the Adolescent and Young Adult (AYA) population, an age range defined as 15 – 29 years by the presenters.

16 Mar 2010

Metabolic drugs top the list of prescription drug expenses for elderly Medicare beneficiaries

Purchases of cholesterol and diabetes prescription drugs by elderly Medicare beneficiaries reached nearly $19 billion in 2007 - about one-fourth of the approximately $82 billion spent for medications for the elderly, according to the latest AHRQ News and Numbers.

16 Mar 2010

Tel Aviv University researcher uses magic tricks to treat children with locomotor disabilities

It's often hard to motivate youngsters with physical disabilities. But a new approach from a Tel Aviv University researcher bridges the worlds of behavior and science to help kids with paralysis and motor dysfunction improve their physical skills and inner confidence -- using a trick up her sleeve called "magic."

16 Mar 2010

Positive results from Phase IIa epilepsy study of ICA-105665

Icagen, Inc. today reported positive results in its Phase IIa epilepsy study of ICA-105665, the Company's novel orally available small molecule KCNQ potassium channel agonist.

16 Mar 2010

Gardasil vaccine: Two complaints filed in Washington Federal Claims court

Anapol Schwartz attorneys Lawrence Cohan and Melissa Fry Hague recently filed two Gardasil vaccine complaints – one on behalf of a Kensington, Calif., family, whose 15-year old daughter died after suffering from severe adverse reactions, and another on behalf of a 19-year old Lapeer, Mich., woman, who has a chronic, autoimmune disorder. The cases, filed in The Court of Federal Claims in Washington, D.C., seek recovery under the National Vaccine Injury Compensation Program.

15 Mar 2010

Surprise stimulus temporarily blinds subsequent events

Reading this story requires you to willfully pay attention to the sentences and to tune out nearby conversations, the radio and other distractions. But if a fire alarm sounded, your attention would be involuntarily snatched away from the story to the blaring sound.

15 Mar 2010

Nervous System News and Research

Latest Nervous System News and Research

InvestorSoup.com announces investment report featuring Somaxon Pharmaceuticals

FDA approves Somaxon Pharmaceuticals' Silenor for treatment of insomnia

Acne drug prevents HIV breakout

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

Positive preliminary results from MediciNova's Phase Ib clinical trial of MN-221 for COPD

Findings from Study 305 evaluating the effect of Northera reported

Toxins released by certain microalgae can contaminate seafood and become toxic to humans

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

CNS Network purchases Logos Technologies' pro-active EDC system for streamlining clinical trials

StockPreacher.com: ACAD reports net loss of $8.7M for fourth-quarter of 2009

Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications

Researchers identify a novel way to study species-specific reproductive behavior

Blocking RhoA enzyme increases survival in SMA mouse model

CogniFit Personal Coach brain training software improves cognitive function of MS patients

Minimal improvements made in survival rates of AYA population with cancer

Metabolic drugs top the list of prescription drug expenses for elderly Medicare beneficiaries

Tel Aviv University researcher uses magic tricks to treat children with locomotor disabilities

Positive results from Phase IIa epilepsy study of ICA-105665

Gardasil vaccine: Two complaints filed in Washington Federal Claims court

Surprise stimulus temporarily blinds subsequent events

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Nervous System News and Research

Latest Nervous System News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in